profit from every $100 of sales.
$0$100
Steris
$264.32+4.29% today
+1.5% in 1 year
1-year low $199.401-year high $268.65
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2026.
0%20% a year
You pay $32.81 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Steris sold, what it kept, and what it did with the cash.
Sales went from $4.54 billion in 2023 to $5.94 billion in 2026, with $782 million of profit last year.
SalesProfit
Steris handed back 49% of the cash it generated last year.
Buybacks $236M$242M
Free cash flow 2026$972M
Bought back its own shares$236M
Paid as dividends$242M
Cash vs. debt$440M vs. $2.1B
Steris vs. similar companies
Steris grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Steris | 32.8× · Expensive | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price | ||
 Glaukos | No profit yet |
Compare Steris with Edwards Lifesciences · Intuitive Surgical
AI analysis
An AI analyst reads Steris's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 3,108 | 4,223 | 4,536 | 5,139 | 5,460 | 5,936 | |
| 1,343 | 1,883 | 1,981 | 2,218 | 2,403 | 2,627 | |
| 548 | 478 | 792 | 862 | 961 | 1,106 | |
| 774 | 1,009 | 1,344 | 1,412 | 1,359 | 1,595 | |
| 397 | 244 | 107 | 378 | 615 | 782 | |
| 4.63 | 2.48 | 1.07 | 3.81 | 6.20 | 7.93 | |
| 43.2% | 44.6% | 43.7% | 43.2% | 44.0% | 44.2% | |
| 17.6% | 11.3% | 17.5% | 16.8% | 17.6% | 18.6% | |
| 12.8% | 5.8% | 2.4% | 7.4% | 11.3% | 13.2% |
Balance sheet
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Total assets | 6,574 | 11,424 | 10,822 | 11,064 | 10,147 | 10,737 |
| Cash | 221 | 348 | 208 | 207 | 172 | 440 |
| Total debt | 1,780 | 3,243 | 3,248 | 3,383 | 2,203 | 2,087 |
| Total liabilities | 2,683 | 4,879 | 4,735 | 4,748 | 3,531 | 3,540 |
| 3,881 | 6,532 | 6,077 | 6,302 | 6,603 | 7,184 | |
| 86 | 98 | 100 | 99 | 99 | 99 | |
| 7.7% | 3.7% | 6.7% | 6.9% | 7.9% | 9.4% | |
| 10.2% | 3.7% | 1.8% | 6.0% | 9.3% | 10.9% |
Cash flow
| In millions of USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| 690 | 685 | 757 | 973 | 1,148 | 1,341 | |
| 239 | 288 | 362 | 360 | 370 | 369 | |
| 450 | 397 | 395 | 613 | 778 | 972 | |
| Dividends paid | 134 | 163 | 183 | 201 | 220 | 242 |
| 15 | 56 | 309 | 12 | 211 | 236 | |
| 26 | 58 | 39 | 57 | 57 | 62 |
Valuation
- 32.8×
- 23.8×
- 2.89
- 2.7×
- 4.3×
- 26.4×
- 17.1×
- 3.8%
- 3.0%
- 1.2%
Profitability
- 44.2%
- 18.6%
- 13.2%
- 22.6%
- 8.5%
- 5.0%
- 11.0%
- 7.3%
- 11.5%
- 1.9%
Growth
- +13.8%
- +11.4%
- +25.0%
- +9.3%
- +0.2%
Financial health
- 1.0×
- 0.02
- 1.1%
- 18.2×
- 2.09
- 1.54
- 0.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 36%of 952
Top 26%of 884
Bottom 39%of 601
Top 39%of 886
Top 30%of 987
What analysts expect
- Average price target
- $256.67
- Range
- $245.00 – $265.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 2.83 | 2.86 | −1.0% |
| Feb 4, 2026 | 2.53 | 2.53 | +0.0% |
| Nov 5, 2025 | 2.47 | 2.35 | +5.1% |
| Aug 6, 2025 | 2.34 | 2.26 | +3.5% |
| May 14, 2025 | 2.74 | 2.60 | +5.4% |
| Feb 5, 2025 | 2.32 | 2.33 | −0.4% |
| Nov 6, 2024 | 2.14 | 2.12 | +0.9% |
| Aug 6, 2024 | 2.03 | 1.98 | +2.5% |
1.2%of the share price, paid each year
On $1,000 invested$12a year at today's yield, before tax
+9.3%2020 to 2025
Raised10 yearsin a row, in our data
Paid per share, each year
$0.96 in 2015 → $2.40 in 2025
How safe it looks
30.9% of its profit
Room to growStretchedMore than it earns: 24.9%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
52No pass
Benjamin Graham
49No pass
Philip Fisher
54No pass
Peter Lynch
38No pass
Joel Greenblatt
16No pass
Charlie Munger
47No pass
Terry Smith
48No pass
Questions about Steris
Is Steris a good stock to buy?
A solid business, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Steris AI analysis
What does Steris do?
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. It is in Medical - Devices, based in Mentor, OH, United States, with 17,937 employees.
Does Steris pay a dividend?
Yes. At today's price the dividend is 1.2% a year, about 31% of its yearly profit. In 2026 it paid out $242 million in dividends.
Is Steris stock halal?
Yes. Steris passes our halal screen: its business is permitted and its debt is 8% of its market value, under the 30% limit. How we check
How has Steris stock done over the past year?
Up 1.5% over the past twelve months, to $264.32. It traded between $199.40 and $268.65, close to its high.
Who are Steris's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Zimmer Biomet Holdings and Glaukos. The peers table on this page compares their profit, growth and price with Steris's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.